SK biopharmaceuticals Co., Ltd.

Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.

326030 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 경기도 성남시 분당구 판교역로 221, 성남시
Website:: https://www.skbp.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK biopharmaceuticals Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
2025-09-16 00:00	Regulatory News Service 투자판단관련주요경영사항	Korean	12.8 KB
2025-08-29 00:00	Regulatory News Service 대규모기업집단현황공시[분기별공시(개별회사용)]	Korean	5.9 KB

Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Infant Bacterial Therapeutics Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.	Sweden	IBT
Intercure Ltd. Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.	Israel	INCR
Intervacc AB Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.	Sweden	IVACC
iNtRON Biotechnology, Inc. Develops phage therapeutics and molecular diagnostics to combat infectious diseases.	South Korea	048530
Inventage Lab Inc. Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.	South Korea	389470
Ipsen Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.	France	IPN
IRLAB Therapeutics Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.	Sweden	IRLAB
ISU Abxis Co., Ltd. Developing antibody-based immunotherapies for oncology and rare diseases.	South Korea	086890
IVF HARTMANN Holding AG Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.	Switzerland	VBSN
Japan Tissue Engineering Co., Ltd. Pioneers regenerative medicine with tissue products, CDMO services, and research models.	Japan	7774